Those who think that Medicare isn’t restricting on new therapies, think again. By cutting reimbursement to new cancer drugs, they are essentially preventing hospitals from giving it:
. . . the companies say Medicare’s data must be inaccurate and that no hospital will offer the drugs to Medicare patients if it is losing $10,000 or more on each treatment.
Patients lose.
